On November 12, 2009, Chesworth, Richard; Shapiro, Gideon; Chantigny, Yves; Mancuso, John; Deziel, Robert published a patent.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of azabicyclo[2.2.1]heptan-2-yl compounds as HDAC inhibitors and therapeutic uses thereof. And the patent contained the following:
Inhibitors of histone deacetylase of general formula I (wherein R4 is H, C1-C6alkyl, C2-C6 alkenyl, etc.; each A is N, N-oxide, -CH=, and -C(R4)=; Z is -N(R1)OR2 or H; L is a covalent bond or -C0-C3alkyl-N(OR2)-; G2 is C or N; U2 is a covalent bond, -C1-C6alkyl, C3-C6cycloalkyl, etc.; R200, R201, R202 and R203 are independently H, C1-C6alkyl, aryl, etc.; B3 is H, aryl, heteroaryl, etc.; R1 and R2 are independently H, C1-C6alkyl, aryl, etc.) are described together with methods for treating various disorders with such compounds Such disorders include Huntington’s disease, dentatorubralpallidoluysian atrophy, spinal and bulbar muscular atrophy, and spinocerebellar ataxias. Synthetic procedures for preparing I are exemplified, but no biol. data is given. Example compound II was prepared in a 5-step synthesis that involved reaction of intermediate (1S,4S)-2-benzhydryl-2,5-diazabicyclo[2.2.1]heptane 2HCl with Et 2-(methylsulfonyl)pyrimidine-5-carboxylate and reaction of the intermediate formed with hydroxylamine. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
The Article related to azabicycloheptanyl compound preparation hdac inhibitor nervous system disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics